SpaceX's highly anticipated IPO is finally here, and Brian Belley and Scott Kitun break down what it means for retail investors. They discuss the performance of pre-IPO vehicles like Republic's mirror tokens, the challenges faced by some secondary market allocations, and why investors should understand the structure behind SPVs, syndicates, and private market access before chasing the next hot IPO. The conversation also explores how investors should think about valuation, long-term conviction, and avoiding emotional decision-making when high-profile companies hit public markets.

In the second half, Brian welcomes Teddy Lyons to review Rejuvenate Bio, a gene therapy company focused on aging-related diseases. Teddy explains the company's unique strategy of commercializing animal-health applications first, supported by partnerships with major industry players including Merck Animal Health. The discussion covers the company's technology, revenue opportunities, development milestones, and why Kingscrowd Capital is closely evaluating the deal.